Literature DB >> 28434822

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Gerda B Toth1, Csanad G Varallyay2, Andrea Horvath1, Mustafa R Bashir3, Peter L Choyke4, Heike E Daldrup-Link5, Edit Dosa6, John Paul Finn7, Seymur Gahramanov8, Mukesh Harisinghani9, Iain Macdougall10, Alexander Neuwelt11, Shreyas S Vasanawala12, Prakash Ambady1, Ramon Barajas2, Justin S Cetas13, Jeremy Ciporen13, Thomas J DeLoughery14, Nancy D Doolittle1, Rongwei Fu15, John Grinstead16, Alexander R Guimaraes2, Bronwyn E Hamilton2, Xin Li17, Heather L McConnell1, Leslie L Muldoon1, Gary Nesbit2, Joao P Netto18, David Petterson2, William D Rooney17, Daniel Schwartz19, Laszlo Szidonya1, Edward A Neuwelt20.   

Abstract

Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material. Published by Elsevier Inc.

Entities:  

Keywords:  chronic kidney disease; magnetic resonance imaging; nephrotoxicity

Mesh:

Substances:

Year:  2017        PMID: 28434822      PMCID: PMC5505659          DOI: 10.1016/j.kint.2016.12.037

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  107 in total

1.  MRI using ferumoxytol improves the visualization of central nervous system vascular malformations.

Authors:  Edit Dósa; Suchita Tuladhar; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt
Journal:  Stroke       Date:  2011-04-14       Impact factor: 7.914

2.  Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide.

Authors:  Joana Ramalho; Richard C Semelka; Mamdoh AlObaidy; Miguel Ramalho; Renato H Nunes; Mauricio Castillo
Journal:  Eur Radiol       Date:  2016-02-24       Impact factor: 5.315

3.  Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.

Authors:  Peigang Ning; Evan J Zucker; Pamela Wong; Shreyas S Vasanawala
Journal:  Magn Reson Imaging       Date:  2015-10-28       Impact factor: 2.546

4.  Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.

Authors:  Eric M Thompson; Daniel J Guillaume; Edit Dósa; Xin Li; Kellie J Nazemi; Seymur Gahramanov; Bronwyn E Hamilton; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2012-04-19       Impact factor: 4.130

5.  Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A Pilot Investigation.

Authors:  David M Hasan; Matthew Amans; Tarik Tihan; Christopher Hess; Yi Guo; Soonmee Cha; Hua Su; Alastair J Martin; Michael T Lawton; Edward A Neuwelt; David A Saloner; William L Young
Journal:  Transl Stroke Res       Date:  2012-07       Impact factor: 6.829

Review 6.  The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.

Authors:  J S Wolf; M Cher; M Dall'era; J C Presti; H Hricak; P R Carroll
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

7.  Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice.

Authors:  Christoph Bremer; Mona Mustafa; Alex Bogdanov; Vasilis Ntziachristos; Alexander Petrovsky; Ralph Weissleder
Journal:  Radiology       Date:  2003-01       Impact factor: 11.105

Review 8.  Peripheral arterial disease in patients with diabetes.

Authors:  Steven P Marso; William R Hiatt
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

9.  Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization.

Authors:  Susanne Wagner; Jörg Schnorr; Antje Ludwig; Verena Stangl; Monika Ebert; Bernd Hamm; Matthias Taupitz
Journal:  Int J Nanomedicine       Date:  2013-02-20

10.  Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study.

Authors:  Saroj Vadhan-Raj; David C Ford; Naomi V Dahl; Kristine Bernard; Zhu Li; Lee F Allen; William E Strauss
Journal:  Am J Hematol       Date:  2016-02       Impact factor: 10.047

View more
  91 in total

1.  Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.

Authors:  Derek Reichel; Bien Sagong; James Teh; Yi Zhang; Shawn Wagner; Hongqiang Wang; Leland W K Chung; Pramod Butte; Keith L Black; John S Yu; J Manuel Perez
Journal:  ACS Nano       Date:  2020-06-23       Impact factor: 15.881

2.  Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma.

Authors:  R F Barajas; D Schwartz; H L McConnell; C N Kersch; X Li; B E Hamilton; J Starkey; D R Pettersson; J P Nickerson; J M Pollock; R F Fu; A Horvath; L Szidonya; C G Varallyay; J J Jaboin; A M Raslan; A Dogan; J S Cetas; J Ciporen; S J Han; P Ambady; L L Muldoon; R Woltjer; W D Rooney; E A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-11       Impact factor: 3.825

Review 3.  Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Authors:  Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2021-04-19

4.  Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type AI/II.

Authors:  Guankui Wang; Natalie J Serkova; Ernest V Groman; Robert I Scheinman; Dmitri Simberg
Journal:  Mol Pharm       Date:  2019-09-26       Impact factor: 4.939

Review 5.  Noncontrast MR angiography: An update.

Authors:  Robert R Edelman; Ioannis Koktzoglou
Journal:  J Magn Reson Imaging       Date:  2018-12-19       Impact factor: 4.813

Review 6.  Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.

Authors:  Seyed Mohammadali Dadfar; Karolin Roemhild; Natascha I Drude; Saskia von Stillfried; Ruth Knüchel; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2019-01-11       Impact factor: 15.470

7.  Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging of the Central Nervous System.

Authors:  Eric M Gale; Peter Caravan
Journal:  ACS Chem Neurosci       Date:  2018-02-12       Impact factor: 4.418

8.  Letter to the Editor: Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Neuroendocrine Tumor.

Authors:  Victoria R Rendell; Matthias R Mühler; Emily R Winslow; Scott B Reeder
Journal:  J Gastrointest Surg       Date:  2019-05-31       Impact factor: 3.452

Review 9.  The role of imaging in pulmonary hypertension.

Authors:  Meenal Sharma; Andrew T Burns; Kelvin Yap; David L Prior
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

10.  Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Authors:  Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.